Bildkälla: Stockfoto

Medivir Q3 2023: The Case for Fostrox Strengthens - Redeye

Redeye comments on Medivir's Q3 report and on the new positive data from 18 patients in the liver cancer trial treated with fostrox + Lenvima. We raise our base case and remodel our bull and bear cases to better reflect potential outcomes with fostrox.

Redeye comments on Medivir's Q3 report and on the new positive data from 18 patients in the liver cancer trial treated with fostrox + Lenvima. We raise our base case and remodel our bull and bear cases to better reflect potential outcomes with fostrox.
Börsvärldens nyhetsbrev
ANNONSER